Sedor Pharmaceuticals Files NDA for CE-Fosphenytoin for Status Epilepticus

Sedor Pharmaceuticals Files NDA for CE-Fosphenytoin for Status Epilepticus Potential significant advance in the treatment of life-threatening condition May 30, 2018, 10:00 AM Eastern Standard Time PAOLI, Pa.,–(BUSINESS WIRE)— Sedor Pharmaceuticals, LLC (Sedor) announced that it has filed with the US FDA an NDA for the approval of Sedor’s lead program, IM/IV Captisol-Enabled™ (CE) Fosphenytoin […]

Sedor Pharmaceuticals Receives Major Milestone Payment

Sedor Pharmaceuticals Receives Major Milestone Payment Payment from Xi’an Xintong Pharmaceutical Research Co. anchors opportunity for Sedor portfolio in People’s Republic of China May 30, 2018, 07:30 AM Eastern Standard Time PAOLI, Pa., Shanxi Province, PRC–(BUSINESS WIRE)—Sedor Pharmaceuticals, LLC (Sedor) and Xi’an Xintong Pharmaceutical Research Co., Ltd (Xintong) announce that Xintong has provided Sedor with […]

Sedor Pharmaceuticals and Los Altos Pharmaceuticals sign license agreement for People’s Republic of China

Sedor Pharmaceuticals and Los Altos Pharmaceuticals sign license agreement for People’s Republic of China Agreement extends PRC opportunity for Sedor portfolio May 30, 2018, 07:30 AM Eastern Standard Time PAOLI, Pa., Los Altos Hills, CA–(BUSINESS WIRE)—Sedor Pharmaceuticals, LLC (Sedor) and Los Altos Pharmaceuticals, Inc. (Los Altos) announce that Sedor has granted Los Altos an exclusive […]

RODES Signs Exclusive Captisol® Licensing Agreement

RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs PAOLI, Pa. & SAN DIEGO — (BUSINESS WIRE) — RODES, Inc. and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)announce the signing of exclusive global license and supply agreements for three Captisol-enabled™ (CE) programs. Under the terms of the agreements, for each program Ligand will be eligible […]